MEIP - Epizyme Inc. Is Doing Everything Right But Its Shares Appear Fairly Priced
It should first be noted we did not consult with Epizyme, Inc. in the preparation of this article.
Our analysis concludes Epizyme, Inc.'s (EPZM) is an incredible company and EPZM's product Tazverik could have a bright future treating those who suffer from Follicular Lymphoma. EPZM's Tazverik has a sNDA awaiting approval (PDUFA date of 6/18/2020) for 3rd line Follicular Lymphoma ("FL") label which, if approved, should generate meaningful revenues. The author would remind readers that the s in sNDA mean supplemental because the underlying product has already been approved by the FDA.
However, using peer